mTOR controls kidney epithelia in health and disease

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Grahammer, Florian ^a   Wanner, Nicola ^a   Huber, Tobias B ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

ADPKD; diabetic nephropathy; mTOR; podocyte; tubular transport

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;

ARTICLE; CELL SIZE; CELL SURVIVAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GENETIC DISORDER; GLOMERULOSCLEROSIS; HUMAN; KIDNEY CELL; KIDNEY DISEASE; KIDNEY EPITHELIUM; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; SIGNAL TRANSDUCTION;

ADPKD; DIABETIC NEPHROPATHY; MTOR; PODOCYTE; TUBULAR TRANSPORT;

ANIMALS; EPITHELIAL CELLS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY GLOMERULUS; TOR SERINE-THREONINE KINASES;

EID: 84893842033     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft491     Document Type: Review

References (100)

1. Smith HW. Evolution of the kidney. In: Lectures on the Kidney. Lawrence, KS: University of Kansas Press, 1943, pp. 1-23
2. Smith HW. From Fish to Philosopher. Boston: Little, Brown, 1953
3. Kerr M, Bray B, Medcalf J et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012; 27 (Suppl 3): Iii73-iii80
4. Couser WG, Remuzzi G, Mendis S et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80: 1258-1270
5. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253: 905-909
6. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128
7. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302
8. Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175
9. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-189
10. Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-Arresting rapamycin-receptor complex. Nature 1994; 369: 756-758
11. Sabatini DM, Erdjument-Bromage H, Lui M et al. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43
12. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994; 91: 12574-12578
13. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484
14. Peterson TR, Sengupta SS, Harris TE et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011; 146: 408-420
15. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101
16. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid- induced protein kinase 1 (SGK1). Biochem J 2008; 416: 375-385
17. Facchinetti V, Ouyang W, Wei H et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008; 27: 1932-1943
18. Ikenoue T, Inoki K, Yang Q et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 2008; 27: 1919-1931
19. Lamming DW, Ye L, Sabatini DM et al. Rapalogs and mTOR inhibitors as anti-Aging therapeutics. J Clin Invest 2013; 123: 980-989
20. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 2013; 14: 133-139
21. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-345
22. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23: 744-755
23. Tharaux PL, Huber TB. How many ways can a podocyte die? Semin Nephrol 2012; 32: 394-404
24. Grahammer F, Wanner N, Huber TB. Podocyte regeneration: Who can become a podocyte? Am J Pathol 2013; 183: 333-335
25. Buch T, Heppner FL, Tertilt C et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2005; 2: 419-426
26. Guo JK, Marlier A, Shi H et al. Increased tubular proliferation as an adaptive response to glomerular albuminuria. J Am Soc Nephrol 2012; 23: 429-437
27. Wiggins RC. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214
28. Inoki K, Mori H, Wang J et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196
29. Godel M, Hartleben B, Herbach N et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209
30. Fukuda A, Chowdhury MA, Venkatareddy MP et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012; 23: 1351-1363
31. Inoki K, Huber TB. Mammalian target of rapamycin signaling in the podocyte. Curr Opin Nephrol Hypertens 2012; 21: 251-257
32. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492
33. Torras J, Herrero-Fresneda I, Gulias O et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24: 3632-3640
34. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326-333
35. Munivenkatappa R, Haririan A, Papadimitriou JC et al. Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF. Histol Histopathol 2010; 25: 189-196
36. Stallone G, Infante B, Pontrelli P et al. Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on slit diaphragm- associated proteins. Transplantation 2011; 91: 997-1004
37. Biancone L, Bussolati B, Mazzucco G et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010; 10: 2270-2278
38. Vollenbroker B, George B, Wolfgart M et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009; 296: F418-F426
39. Vogelbacher R, Wittmann S, Braun A et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499
40. Canaud G, Bienaimé F, Viau A et al. The essential role of Akt2 in podocytes. Nat Med 2013; 19:1288-1296
41. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009; 20: 2493-2502
42. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011; 79: 502-511
43. Ito N, Nishibori Y, Ito Y et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest 2011; 91: 1584-1595
44. Rangan GK, Coombes JD. Renoprotective effects of sirolimus in nonimmune initiated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2007; 22: 2175-2182
45. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuriaassociated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072
46. Naumovic R, Jovovic D, Basta-Jovanovic G et al. Effects of rapamycin on active Heymann nephritis. Am J Nephrol 2007; 27: 379-389
47. Kurayama R, Ito N, Nishibori Y et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest 2011; 91: 992-1006
48. Yang Y, Wang J, Qin L et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007; 27: 495-502
49. Niranjan T, Bielesz B, Gruenwald A et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14: 290-298
50. Dai C, Stolz DB, Kiss LP et al.Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20: 1997-2008
51. Kato H, Gruenwald A, Suh JH et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem 2011; 286: 26003-26015
52. Shkreli M, Sarin KY, Pech MF et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat Med 2012; 18: 111-119
53. Simons M, Huber TB. Old friends form alliance against podocytes. Kidney Int 2011; 80: 1117-1119
54. Wang D, Dai C, Li Y et al. Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int 2011; 80: 1159-1169
55. Luo ZF, Feng B, Mu J et al. Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: Regulation of endoplasmic reticulum stress-oxidative activation. Toxicol Appl Pharmacol 2010; 246: 49-57
56. Eid AA, Ford BM, Bhandary B et al. Mammalian target of rapamycin regulates nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 2013; 62: 2935-2947
57. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 2010; 22: 132-139
58. Hartleben B, Godel M, Meyer-Schwesinger C et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010; 120: 1084-1096
59. Cina DP, Onay T, Paltoo A et al. Inhibition of mTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012; 23: 412-420
60. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168
61. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293
62. Lamming DW, Ye L, Katajisto P et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-1643
63. Sagrinati C, Netti GS, Mazzinghi B et al. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006; 17: 2443-2456
64. Smeets B, Uhlig S, Fuss A et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol 2009; 20: 2604-2615
65. Appel D, Kershaw DB, Smeets B et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20: 333-343
66. Bollee G, Flamant M, Schordan S et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17: 1242-1250
67. Smeets B, Kuppe C, Sicking EM et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1262-1274
68. Chiu T, Santiskulvong C, Rozengurt E. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005; 288: G182-G194
69. Golbaekdal K, Nielsen CB, Djurhuus JC et al. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation 1994; 58: 1153-1157
70. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
71. Morales JM, Andres A, Dominguez-Gil B et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc 2003; 35(Suppl 3): 154S-156S
72. Kempe DS, Dermaku-Sopjani M, Frohlich H et al. Rapamycin-induced phosphaturia. Nephrol Dial Transplant 2010; 25: 2938-2944
73. Haller M, Amatschek S, Wilflingseder J et al. Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. PLoS One 2012; 7: E39229
74. Lu M, Wang J, Jones KT et al. mTOR complex-2 activates ENaC by phosphorylating SGK1. J Am Soc Nephrol 2010; 21: 811-818
75. Lang F, Artunc F, Vallon V. The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr Opin Nephrol Hypertens 2009; 18: 439-448
76. Lu M, Wang J, Ives HE et al. mSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel. J Biol Chem 2011; 286: 30647-30654
77. Pearce LR, Sommer EM, Sakamoto K et al. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J 2011; 436: 169-179
78. Lieberthal W, Fuhro R, Andry C et al. Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance. Transplantation 2006; 82: 17-22
79. Mundinger GS, Munivenkatappa R, Drachenberg CB et al. Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation. Transplantation 2013; 95: 1204-1210
80. Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: Neurological, renal and pulmonary manifestations. Neuropediatrics 2010; 41: 199-208
81. Siroky BJ, Yin H, Bissler JJ. Clinical and molecular insights into tuberous sclerosis complex renal disease. Pediatr Nephrol 2011; 26: 839-852
82. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132
83. Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824
84. Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 2012; 46: 267-275
85. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485
86. Tao Y, Kim J, Schrier RW et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51
87. Shillingford JM, Piontek KB, Germino GG et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21: 489-497
88. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
89. Wahl PR, Serra AL, Le Hir M et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604
90. Wu M, Wahl PR, Le Hir M et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259
91. Zafar I, Ravichandran K, Belibi FA et al. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 2010; 78: 754-761
92. Klingel R, Dippold W, Storkel S et al. Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma. Am J Kidney Dis 1992; 19: 22-30
93. Audenet F, Yates DR, Cancel-Tassin G et al. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: Genomics towards personalized medicine. BJU Int 2012; 109: 1864-1870
94. Distefano G, Boca M, Rowe I et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009; 29: 2359-2371
95. Boehlke C, Kotsis F, Patel V et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 2010; 12: 1115-1122
96. Takiar V, Nishio S, Seo-Mayer P et al. Activating AMP-Activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 2011; 108: 2462-2467
97. Perico N, Antiga L, Caroli A et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031-1040
98. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
99. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
100. Ma M, Tian X, Igarashi P et al. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 2013; 45: 1004-1012